Consortium Psychiatricum, Journal Year: 2024, Volume and Issue: 5(4), P. 40 - 62

Published: Dec. 24, 2024

Depression is one of the most common mental disorders and associated with a significant increase in risk somatic comorbidities. The chronobiological theory pathogenesis depression explains relationship between symptoms disturbance circadian rhythm regulation. Disrupted rhythms are also observed other such as alcohol use disorder, anxiety disorders, epilepsy, Parkinson's disease. Therefore, there growing interest medications melatoninergic mechanism action treatment comorbid aforementioned disorders. This review aims to systematically examine evidence for antidepressants (agomelatine fluvoxamine) abuse, (including phobic anxiety, panic, generalized disorders), or neuropsychiatric (such epilepsy disease). systematic included experimental studies, reviews, meta-analyses published English Russian, which examined fluvoxamine agomelatine adult patients recurrent depressive disorder (ICD-10) major (DSM-5) search was conducted PubMed, Cochrane Library eLIBRARY scientific databases. quality selected studies assessed using Risk Bias tool, used evaluate errors clinical studies. results were presented narrative synthesis grouped by comorbidities evaluated. A total 20 articles reviewed (with pooled sample size n=1,833 participants). suggest that might help reducing symptoms, improve sleep, decrease cravings, alleviate severity motor Moreover, pharmacogenetic testing select medication dosage may enhance its therapeutic effectiveness. demonstrates lack data guidelines on In this regard, it currently difficult draw definitive conclusion regarding efficacy safety these Available an improvement manifestations Future research directions include development implementation double-blind, randomized trials study

Language: Английский